so-c101
Recombinant proteinexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 13, 2019 (NCT04234113)
Timeline
Indications
Studied for
- Anus Neoplasms · Phase 1
- Biliary Tract Neoplasms · Phase 1
- Carcinoma, Hepatocellular · Phase 2
- Carcinoma, Merkel Cell · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Renal Cell · Phase 1
- Carcinoma, Squamous Cell · Phase 2
- Colorectal Neoplasms · Phase 2
- Melanoma · Phase 1
- Mesothelioma · Phase 1
- Microsatellite Instability · Phase 1
- Ovarian Neoplasms · Phase 2
- Prostatic Neoplasms, Castration-Resistant · Phase 2
- Small Cell Lung Carcinoma · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 1
- Stomach Neoplasms · Phase 1
- Thymus Neoplasms · Phase 1
- Thyroid Gland · Phase 1
- Thyroid Neoplasms · Phase 1
- Triple Negative Breast Neoplasms · Phase 1
- Urinary Bladder Neoplasms · Phase 1
- Uterine Cervical Neoplasms · Phase 1
Mechanism of action
- Interleukin-15AGONIST
IL15 agonist
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05619172 | Phase 2 | Dec 31, 2022 | Accord Research |
| NCT05256381 | Phase 2 | Jun 21, 2022 | Accord Research, Merck |
| NCT04234113 | Phase 1 | Jun 13, 2019 | Accord Research |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Accord Research | For profit | 3 | 3 | 2 | 2019 |
| Merck | For profit | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1